Gloghini A, Volpe R, Canzonieri V, Carbone A
Division of Pathology, Centro Regionale di Riferimento Oncologico, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.
Virchows Arch A Pathol Anat Histopathol. 1991;418(4):355-60. doi: 10.1007/BF01600166.
A monoclonal antibody (Ki-M6) against the CD 68 antigen, which labels cells of the monocyte/macrophage system, was tested on Bouin-fixed, paraffin-embedded samples of normal, reactive and neoplastic tissues by an avidin-biotin-peroxidase complex method, with the aim of establishing its value in diagnostic pathology. In normal human tissues, Ki-M6 reactivity was confined to the so-called resident macrophages populating normal organs under physiological conditions. Moreover, restricted reactivity against cells of macrophage lineage was observed in reactive and inflammatory lesions. Granulocytes, monocyte/macrophage-related immune accessory cells, and other analysed normal tissue structures did not reveal any reactivity. Ki-M6 was strongly reactive with the cases of benign (4/4) and malignant (15/15) fibrous histiocytomas, in addition to the true histiocytic lymphomas (3/3). Cases of granular cell tumour (2/3) showed strong reactivity with Ki-M6, whereas only few immunoreactive cells, with weak staining, were seen in the other Ki-M6-positive neoplasms [neurofibroma (3/3), benign schwannoma (1/2), ganglioneuroma (1/1), malignant schwannoma (5/9), melanoma (9/28), dermatofibrosarcoma protuberans (1/1), myelomonocytic leukaemia (3/3)]. Among the epithelial malignancies tested (47 cases), Ki-M6 was positive only in renal cell carcinoma (11/14). Malignant lymphomas of the Hodgkin (56 cases) and non-Hodgkin type (67 cases) were uniformly non-reactive. From these data, Ki-M6 appears to be an excellent marker of monocyte/macrophage-related cells and appears to be a reliable indicator for fibrous histiocytomas and true histiocytic malignancies. The availability of this additional antibody capable of staining routinely processed tissue is of practical interest.
一种针对CD 68抗原的单克隆抗体（Ki-M6），可标记单核细胞/巨噬细胞系统的细胞，采用抗生物素蛋白-生物素-过氧化物酶复合物法，在经Bouin固定、石蜡包埋的正常、反应性和肿瘤性组织样本上进行检测，目的是确定其在诊断病理学中的价值。在正常人体组织中，Ki-M6反应性局限于生理条件下在正常器官中存在的所谓常驻巨噬细胞。此外，在反应性和炎性病变中观察到对巨噬细胞系细胞的局限性反应。粒细胞、单核细胞/巨噬细胞相关免疫辅助细胞以及其他分析的正常组织结构未显示任何反应性。除了真性组织细胞淋巴瘤（3/3）外，Ki-M6与良性（4/4）和恶性（15/15）纤维组织细胞瘤病例呈强反应性。颗粒细胞瘤病例（2/3）与Ki-M6呈强反应性，而在其他Ki-M6阳性肿瘤[神经纤维瘤（3/3）、良性神经鞘瘤（1/2）、神经节神经瘤（1/1）、恶性神经鞘瘤（5/9）、黑色素瘤（9/28）、隆突性皮肤纤维肉瘤（1/1）、骨髓单核细胞白血病（3/3）]中仅见少数免疫反应性细胞，染色较弱。在所检测的上皮性恶性肿瘤（47例）中，Ki-M6仅在肾细胞癌（11/14）中呈阳性。霍奇金淋巴瘤（56例）和非霍奇金淋巴瘤（67例）均无反应性。根据这些数据，Ki-M6似乎是单核细胞/巨噬细胞相关细胞的优良标志物，似乎是纤维组织细胞瘤和真性组织细胞恶性肿瘤的可靠指标。这种能够对常规处理组织进行染色的额外抗体的可用性具有实际意义。
